accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase
Year: 2008
Type: article
Authors: Yaping Shou, Hagop M. Kantarjian, Yok‐Lam Kwong, Michele Baccarani, Timothy P. Hughes, Giovanni Martinelli, Jerald P. Radich, Andreas Hochhaus, François‐Xavier Mahon, Giuseppe Saglio, Marco Gobbi, Jane F. Apperley, Richard A. Larson, Elisabetta Abruzzese, Stephen G. O’Brien, Oliver G. Ottmann, Francis J. Giles, Dong‐Wook Kim, Jorge E. Cortés
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W350434498